Introduction
Multiple myeloma (MM) is an incurable drug-resistant clonal B cell malignant neoplasm localised to the bone marrow. Janus kinases (JAKs) are well-characterised signalling kinases comprising four family members JAK1, JAK2, JAK3 and TYK2 that are important in haematological malignancy, as JAK mutations have been shown to contribute to the pathogenesis of both myeloproliferative disorders [1] [2] [3] and leukaemias. 4 JAKs have an established role in signalling for many cells (reviewed by Rane and Reddy 5 ), and in MM, JAKs are activated by a variety of cytokines including interleukin-6 (IL-6), 6, 7 interferon-a 6, 8 and epidermal growth factor. 6 Many pathways downstream of JAKs are exploited by malignant cells; the role of IL-6 and its subsequent activation of JAK/signal transducers and activators of transcription (STAT) is possibly the most studied pathway in MM. Some human myeloma cell lines (HMCL) cannot proliferate or survive without exogenous IL-6, 9,10 and some conventional drugs are ineffective in the presence of IL-6.
11-13
The bone marrow microenvironment, known to provide supportive signals to MM cells, produces IL-6; 14 hence, reducing the pro-survival effect of IL-6 may abrogate the drugresistant phenotype of MM. CD45 is a phenotypic marker expressed by some myeloma cells, which has been reported to influence IL-6 responsiveness. 15 It is therefore likely that CD45 expression might affect sensitivity to JAK inhibitors.
CYT387 is a novel JAK inhibitor that can inhibit JAK1, JAK2, JAK3 and TYK2 kinase activity. 16, 17 The structure and development of the compound has recently been described. 18 Several JAK inhibitors are currently in various stages of development and investigation for use in MM including INCB000020, 19 
INCB16562
, 20 AG490, 21, 22 AZD1480 (ref. 23) and Pyridone 6, 24 or for other haematological malignancies such as WP1066 in AML. 25 CYT387 has recently undergone Phase I evaluation, demonstrating safe use of low micromolar concentrations, with no relevant haematological toxicities evident. 26 Given the tolerance of CYT387 in patients and the putative role of IL-6 in MM drug resistance, JAK inhibitors are being investigated for their potential use as a single agent or in combination therapy for MM. Furthermore, preliminary in vitro data has demonstrated the potential of JAK/STAT inhibition to sensitise MM cells to conventional therapies. 20, 22 Here we show that the JAK inhibitor CYT387 can modulate IL-6-stimulated signalling within HMCL, which can sensitise them to various other anti-MM treatments. CYT387 can inhibit proliferation and disrupt the cell cycle of MM cells. Finally, CYT387 induces apoptosis as a single agent and synergises with melphalan and bortezomib, when used against either HMCL or primary MM tumour cells.
Materials and methods

Reagents
The JAK1/2 inhibitor CYT387 was kindly provided by YM BioSciences Australia (Melbourne, Victoria, Australia) and dissolved in dimethyl sulfoxide. The proteasome inhibitor bortezomib (Janssen-Cilag, North Ryde, New South Wales, Australia) was reconstituted in saline. The alkylating agent melphalan (Sigma-Aldrich, Sydney, New South Wales, Australia) was dissolved in 0.5% HCl.EtOH. All stock drug solutions were diluted in complete RPMI-1640 culture medium to various concentrations for experimentation.
Cell lines and culture conditions
HMCL LP-1, NCI-H929, OPM2, RPMI-8226 and U266, and the human stromal cell line HS5, were obtained from the American Type Culture Collection (Manassas, VA, USA). ANBL-6, OCI-MY1 and XG-1 were a kind gift from the Winthrop P Rockefeller Cancer Institute (Little Rock, AR, USA). HMCL were grown and treated at densities between 2.0 and 5.0 Â 10 5 cells/ ml in RPMI-1640 media (Gibco, Invitrogen, Mulgrave, Victoria, Australia) supplemented with 10% heat-inactivated foetal bovine serum (Lonza, Mt Waverley, Victoria, Australia) and 2 mM L-glutamine (Gibco, Invitrogen). IL-6-dependent cell lines were cultured with 2-5 ng/ml IL-6 as required. All cells were cultured in a humidified incubator at 37 1C with 5% CO 2 . All HMCL were passaged 24 h before the experimental setup to ensure high viability and cycling.
Primary samples
Primary MM samples were obtained from bone marrow aspirates from relapsed and refractory MM patients, following written informed consent with approval from the Alfred Hospital Research and Ethics Committee, and isolated and treated as previously described. 27 Briefly, bone marrow mononuclear cells (BMMC) were isolated with Ficoll-Paque Plus (Amersham Biosciences, Rydalmere, New South Wales, Australia), washed in phosphate-buffered saline (PBS), and red blood cells were lysed with NH 4 Cl solution (8.29 g/l ammonium chloride, 0.037 g/l ethylene diamine tetraacetic acid, 1 g/l potassium bicarbonate). Cells were then washed again in PBS and quantitated by haemocytometer. BMMC samples were then cultured in complete RPMI-1640 media (as above for HMCL) for 24 h. Subsequently, the BMMC were plated at 5 Â 10 5 cells/ml and were treated with CYT387 (5-50 mM), alone or (dependant on cell numbers) in combination with bortezomib (5-40 nM) or melphalan (50-200 mM) for 24 and/or 48 h. Drug-induced MM-specific cell apoptosis was then compared with untreated and vehicle controls by staining for CD45 FITC (BD, North Ryde, New South Wales, Australia), CD38 PerCP-Cy5.5 (BD) and Apo 2.7 PE (Immunotech Beckman Coulter, Mt Waverley, Victoria, Australia) to determine apoptosis in CD45ÀCD38 þ MM cells. Samples were subsequently analysed by fluorescence-activated cell sorting (FACS).
Primary bone marrow stromal cells (BMSC) were also collected from patient BMMC and cells that adhered to the flask after an initial 24 h culture were cultured with continued selection for adherent cells over several passages. Once cells had expanded in culture, they were used in coculture (CC) to stimulate MM cells in parallel to experiments utilising the HS5 stromal cell line.
Western blots
HMCL were treated with CYT387 (1 or 2 mM) for 60 min and then stimulated with 10 ng/ml IL-6 for 15 min. Protein lysates of CYT387-treated and -untreated HMCL were made with radioimmunoprecipitation buffer (50 mM Tris.HCl, pH 7.4, 150 mM NaCl, 1 mM phenylmethanesulfonyl fluoride, 1 mM ethylene diamine tetraacetic acid, 5 mg/ml Aprotinin, 5 mg/ml Leupeptin, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS). Briefly, cells were incubated in radioimmunoprecipitation buffer on ice for 30-60 min before being centrifuged at 16 100 g for 20 min at 4 1C and the supernatant collected. Protein concentration was quantified using DC Protein Assay (Bio-Rad, Gladesville, New South Wales, Australia) as per manufacturer's instructions. Subsequently, 100 mg of each protein lysate was separated by 10% SDS-polyacrylamide gel electrophoresis and blotted onto nitrocellulose (Hybond ECL, Amersham Biosciences) using the Bio-Rad semi-dry transfer system. Membranes were blocked with 5% skim milk powder 0.1% Tween-20/PBS for 60 min then incubated with mouse monoclonal antiphospho-STAT3 (pY705, Santa Cruz, ThermoFisher Scientific, Scoresby, Victoria, Australia), mouse monoclonal anti-STAT3 (Santa Cruz) or mouse monoclonal anti-a-tubulin (SigmaAldrich) for 1-2 h at room temperature or overnight at 4 1C. The blots were washed three times for 15 min in 0.1% Tween-20/PBS, then incubated with secondary horseradish peroxidase tagged antibody (swine anti-rabbit Ig HRP or rabbit anti-mouse Ig HRP (Dako, Campbellfield, Victoria, Australia)) for 1-2 h at room temperature before washing as above. Blots were visualised with Supersignal west pico ECL reagents (Pierce, ThermoFisher Scientific).
Intracellular FACS
Activation of the JAK/STAT, PI3K/AKT and Ras/MAPK pathways was investigated using intracellular flow cytometry to measure the phosphorylation of STAT3 at tyrosine 705 (p-STAT3), AKT at serine 473 (p-AKT), and extracellular signal-regulated kinase (ERK)1/2 at threonine 202 and tyrosine 204 (p-ERK). HMCL were stimulated alone with 10 ng/ml IL-6 ± 200 ng/ml insulin-like growth factor-1 (IGF-1) or stimulated in CC with HS5 stromal cells or primary BMSC, with or without CYT387 treatment. For CC, HS5 and primary BMSC were seeded into a 24-well plate at 2 Â 10 5 cells/ml and allowed to establish for 4 h, after which HMCL prestained with CD38 or CD138 FITC (BD) were added. MM cells were stimulated alone (10 ng/ml IL-6, or 5 ng/ml IL-6 and 100 ng/ml IGF-1), or in CC (direct CC with stroma or transwell CC with stroma), with or without either 60 min of CYT387 pretreatment or 15 min CYT387 co-treatment. After stimulation±treatment, MM cells were harvested and fixed with 2% paraformaldehyde for 10-30 min, washed, then permeabilised with methanol overnight. Methanol was washed off and the cells were resuspended in p-STAT3 PE (BD), p-AKT PE (BD) or p-ERK (BD) and stained for 45-60 min at room temperature. Unbound antibody was washed off and the cells resuspended in 2% foetal bovine serum PBS and acquired by FACS.
Proliferation and viability assays
The viability and proliferation of CYT387-treated HMCL anduntreated/vehicle controls were determined using various methods as described previously.
28 Proliferation was measured first using Celltiter 96 AQeous one solution cell proliferation assay MTS reagent (Promega, South Sydney, New South Wales, Australia) on a panel of eight HMCL. Cells were cultured at 2.0 Â 10 5 cells/ml in 100 ml fresh media in 96-well plates for 24, 48 and 72 h with CYT387 (0.1-5 mM). 20 ml of MTS reagent (Promega) was added for the final 4 h of treatment, and the plates were read at 490 nm using a Fluostar Optima plate reader (BMG Labtech, Mornington, Victoria, Australia). The viable cell numbers of a panel of five HMCL that were treated with CYT387, with and without IL-6 co-treatment, was also measured by trypan blue staining and haemocytometer count.
The HMCL NCI-H929, OCI-MY1 and U266 were then selected for further analysis. Apoptosis of CYT387-treated cells was assessed by FACS with Annexin-V and propidium iodide (PI) staining. HMCL were treated for 24 or 72 h with 1 or 5 mM CYT387, then harvested and washed in Annexin Buffer (0.01 HEPES, 0.14 M NaCl, 2.5 mM CaCl 2 , pH 7.4) and stained with Annexin-V FITC (Biosource) made up in Annexin Buffer, for 30 min at room temperature. Unbound antibody was then washed off with Annexin Buffer and cells were resuspended in Annexin Buffer with 62.5 ng/ml PI (Sigma-Aldrich) and analysed by FACS.
For the synergy experiments, HMCL were treated with CYT387 in combination with bortezomib or melphalan for 24 and 48 h before being harvested, and resuspended in FACS Buffer (0.5% heat-inactivated foetal bovine serum in PBS) supplemented with 62.5 ng/ml PI (Sigma-Aldrich). Cells were immediately analysed by FACS. The proportion of PI-positive cells was quantitated by subtracting the background death of untreated cells. Single drug-treated cells were compared with combination-treated cells, and synergism was calculated using Calcusyn software (Biosoft, Cambridge, UK).
Cell cycling
The effect of CYT387 treatment on HMCL cell cycling was measured after 24 and 72 h. CYT387 (0.5, 1 or 5 mM)-treated and -untreated HMCL were harvested, washed in PBS and resuspended in 100 ml PBS. Cells were fixed with 1 ml of cold 70% ethanol while being vortexed. Tubes were stored at À20 1C until analysis. Once all samples were collected, tubes were centrifuged at 500 g for 10 min, the supernatant was carefully removed and the cells were washed in 5 ml PBS. After the final wash, cells were resuspended in 250-500 ml of PI/RNase staining buffer (BD) and incubated in the dark at room temperature for 15 min before being analysed by FACS.
Data analysis
All FACS data was acquired on a BD FACSCalibur and data analysis done using Flowjo 7.6. Software (Treestar, Ashland, OR, USA). All statistical analysis was done using GraphPad Prism 5.03 software (La Jolla, CA, USA).
Results
JAK/STAT signalling is inhibited by CYT387
IL-6 signalling through the JAK/STAT pathway is well characterised in MM cells, with binding of IL-6 to its receptor inducing JAK2 to phosphorylate STAT3. The ability of CYT387 to inhibit JAK2 was first confirmed by measuring the level of STAT3 phosphorylation by western blotting and FACS. HMCL (NCI-H929 and U266) were incubated with CYT387 for 1 h before being stimulated with IL-6 for 15 min to induce p-STAT3. CYT387 (1-2 mM) inhibited the phosphorylation of STAT3 in IL-6 stimulated samples as demonstrated by FACS ( Figure 1a ) and confirmed by western blotting (Figure 1b) . As seen in Figures 1a and b, CYT387 was also able to reduce constitutive levels of p-STAT3 in U266 cells, as well as p-STAT3 induced by exogenous IL-6. Overall, the total STAT3 protein was unaffected by IL-6 stimulation or CYT387 treatment.
Given the importance of the bone marrow microenvironment in MM growth and survival, it was important to establish if CYT387 could similarly modulate signalling in MM cells in CC with BMSC. This was done with both immortalised BMSC (HS5) and primary patient BMSC. In each case, 15 min of CC with BMSC (with or without contact) was able to induce phosphorylation of STAT3 in the MM cells, whereas contemporaneous treatment with CYT387 dramatically reduced the amount of p-STAT3 in the HMCL (Figure 1c and Supplementary Figure 1A and 1B), thus, demonstrating that CYT387 is able to prevent STAT3 activation in MM cells induced by soluble factors within the bone marrow microenvironment, as well as the contactmediated signalling provided to MM by BMSC.
CYT387 inhibits PI3K/AKT and Ras/MAPK signalling JAK signalling kinases are involved in many cellular pathways, which led us to investigate the effect of CYT387 on IL-6 and IGF-1-induced PI3K/AKT, and Ras/MAPK signalling in NCI-H929, OCI-MY1 and U266 cells (Figure 1d ). OCI-MY1 showed distinct p-AKT activation after IL-6 and IGF-1 stimulation that was significantly reduced by CYT387 co-treatment. IL-6 and IGF-1 stimulation induced p-ERK in U266 cells, which was significantly inhibited by CYT387. The levels of p-AKT and p-ERK showed only a small increase in response to IL-6 and IGF-1 stimulation in NCI-H929. IGF-1 can also induce JAK/ STAT signalling, 29, 30 because of this, we confirmed that CYT387 co-treatment was able to significantly inhibit p-STAT3 induced by simultaneous IL-6 and IGF-1 stimulation in all three HMCL (Supplementary Figure 1C) .
CYT387 inhibits proliferation in HMCL
Given that CYT387 can inhibit important signalling pathways in HMCL, we next investigated the effect of CYT387 on proliferation and cycling of the HMCL. The effect of CYT387 (0.1-5 mM) on cell proliferation/viability was measured by MTS assay at 24, 48 and 72 h (Figure 2a ) on a panel of eight HMCL (IL-6 non-responsive, predominantly CD45À phenotypeFLP-1, NCI-H929, OPM2, and RPMI-8226, and IL-6 responsive, predominantly CD45 þ phenotypeFANBL-6, OCI-MY1, U266 and XG-1). Six of the eight HMCL had a time-and dose-dependent response to CYT387, with inhibition in some HMCL within 24 h. At 72 h, NCI-H929 and XG-1 were the most sensitive to CYT387 treatment, demonstrating that CYT387 can be a potent inhibitor of both IL-6-responsive and non-responsive HMCL.
Proliferation of HMCL cultured with CYT387 over 72 h was also assessed by quantitation of viable cell number by haemocytometer (Figure 2b ). Three diverse HMCL (NCI-H929, OCI-MY1 and U266) representing both the IL-6-responsive and non-responsive phenotype were selected to determine the specific effect of CYT387 on absolute cell number. Because of the obvious relationship between IL-6 signalling and the inhibition of JAK2 by CYT387, the proliferation of three HMCL was measured with the addition of IL-6 and/or CYT387. The three HMCL proliferated well in complete media with or without supplementation with 10 ng/ml IL-6, and CYT387 (0.5-1 mM) was able to reduce the proliferation of HMCL in culture even in the presence of IL-6. A single dose of CYT387 inhibited cell proliferation and resulted in a reduction in absolute cell number by 50% in NCI-H929 (1 mM), 50% in OCI-MY1 (0.5 mM) and 44% in U266 (1 mM) after 72 h, compared with untreated controls.
Treatment of HMCL with CYT387 results in an accumulation of cells in G 2 /M phase of the cell cycle
The anti-proliferative effects of CYT387 were further characterised by evaluating the cell cycle of HMCL treated with CYT387. HMCL (NCI-H929, OCI-MY1 and U266) treated with CYT387 (0.5-5 mM) showed a marked accumulation of cells in the G 2 /M phase of the cell cycle. This was most pronounced in NCI-H929 cells, in which there was a 1.5 fold increase in G 2 /M in cells treated with 1 mM CYT387 and a two fold increase in cells treated with 5 mM CYT387 (Figure 2c ), compared with untreated or vehicle-treated controls after 24 and 72 h treatment. An additional polyploid population was found in the 5 mM CYT387 treated samplesFsuggesting that CYT387 treatment causes further aberration from the normal cell cycle of MM cells. This correlated well with the CYT387-induced cytostasis seen in Figure 2b .
CYT387 induces apoptosis in HMCL
After demonstrating the potent effect of CYT387 on cell signalling and proliferation, we next investigated the induction of apoptosis by Annexin-V/PI FACS staining in three HMCL (NCI-H929, OCI-MY1 and U266). An increased proportion of apoptotic cells was detected in all three HMCL, which was most evident in NCI-H929 (Figure 3a) , with a 21 and 52% increase in apoptotic cells detected at 24 and 72 h, respectively, after treatment with 5 mM CYT387 (Figure 3b ). The toxicity of CYT387 (0.5-10 mM) on normal donor peripheral blood mononuclear cells was also investigated after 72 h, with only low levels of apoptosis seen (mean 14% death after 72 h with 5 mM CYT387, data not shown).
CYT387 synergises with other anti-myeloma agents in HMCL
To assess CYT387 as part of a combination therapy, NCI-H929, OCI-MY1 and U266 were treated with a range of doses of CYT387, bortezomib and melphalan to establish dose effect Figure 1 CYT387 prevents signalling downstream of IL-6 or CC stimulation. HMCL were incubated with or without CYT387 (1-2 mM) for 1 h before stimulation with 10 ng/ml IL-6 for 15 min. Cells were then harvested and p-STAT3 (pY705) was measured. (a) By intracellular FACS with the geometric mean fluorescence intensity measured and graphed (n ¼ 3, mean ± s.e., stimulated cells ± CYT387 were analysed using a one-way ANOVA with Tukey post-test *Po0.05, **Po 0.01). (b) By western blot for p-STAT3 (pY705), total STAT3 and a-tubulin as a loading control. (c) p-STAT3 was also induced in HMCL using IL-6, direct CC with HS5 immortalised BMSC or primary BMSC or transwell (TW) 'soluble only' CC with HS5. HMCL were fluorescently labelled with CD38 or CD138 and stimulated for 15 min with or without co-treatment with 2 mM CYT387. Representative plots of NCI-H929, (n ¼ 3, for NCI-H929, OCI-MY1 and U266). (d) NCI-H929, OCI-MY1 and U266 cells were starved overnight and stimulated with 5 ng/ml IL-6 and 100 ng/ml IGF-1 for 15 min, with or without co-treatment with 2 mM CYT387. p-AKT (pS473) and p-ERK1/2 (pT202/pY204) were measured by intracellular FACS with the geometric mean fluorescence intensity normalised to the untreated (UT) control and averaged (n ¼ 4, mean ± s.e., stimulated cells ± CYT387 were analysed using a one-way ANOVA with Tukey post-test *Po0.05).
curves for each drug before combining with CYT387 and measuring the synergy using Calcusyn software. Dose effect curves generated for each compound (melphalan and bortezomib data not shown) show CYT387 (0.5-10 mM) induced apoptosis in three HMCL in a time-and dose-dependent manner (Figure 4a ). CYT387 displayed synergism with both bortezomib (1-4 nM) and melphalan (25-50 mM), but with variations in the degree of synergy seen with different drug dosages and analysis timepoints (Figure 4b) . No distinct pattern of specific drug dose, timepoint or cell line was evident. CYT387 was also combined with the second-generation proteasome inhibitor NPI-0052, as well as other conventional therapies cisplatin, dexamethasone and etoposide, which showed mixed synergistic and antagonistic results (data not shown).
CYT387 induces apoptosis as a single agent and synergises with bortezomib and melphalan in primary MM cells
The effect of CYT387 on ex-vivo primary MM cells was also investigated, both as a single agent and as part of combination therapy. MM patient BMMC were cultured with various doses of CYT387 (5-50 mM) for 24 and 48 h, after which the CD38 þ CD45À MM cell populations were assessed for apoptosis by flow cytometry. Six patients were treated and apoptosis was seen in between 5 and 59% of MM cells treated with 20 mM CYT387 after 48 h (Figure 5a ). The effect of CYT387 (10-20 mM), in combination with melphalan (50-200 mM) and bortezomib (10-40 nM), was also investigated. CYT387 was seen to synergise with melphalan in two of three patients and synergy was also observed with bortezomib in some patients/doses (Figure 5b ).
Discussion
Multiple lines of evidence have confirmed the role of IL-6/JAK/ STAT signalling in MM, including experiments demonstrating the IL-6 dependence of some MM cells, the upregulation of proliferation of MM cells with IL-6, the inhibition of druginduced apoptosis by IL-6, and most important to this investigation, the direct induction of apoptosis in MM cells by inhibition of the IL-6/JAK/STAT pathway. These data and the abundance of IL-6 in the bone marrow microenvironment makes JAK/STAT signalling a rational target for inhibition with new chemotherapeutics and is supported by preliminary in vitro studies that have demonstrated MM cell apoptosis induction via siRNA targeting of the JAK/STAT pathway. 31 Furthermore, the signal transduction role of JAKs in other important pathways (reviewed by Rane and Reddy 5 ) and the pro-survival effects of JAK mutations in other haematological malignancies [1] [2] [3] [4] have already demonstrated the therapeutic potential of JAK inhibition. The therapeutic challenge is to inhibit MM cells in the presence of IL-6 or BMSC. Here, we have expanded upon previous work evaluating JAK inhibition in MM by studying a broader range of HMCL, by demonstrating that CYT387 can inhibit JAK/STAT activation in the context of CC models and by demonstrating the impact of CYT387 on primary MM tumour cells.
It has been hypothesised that in the earlier stages of MM, the malignant cells are predominantly CD45 þ , whereas in more advanced, drug-resistant disease, CD45À MM cells predominate. 32 Moreover, CD45À MM cells are considered less IL-6 responsive and express fewer IL-6 receptors than CD45 þ MM cells. 15 Other studies of JAK inhibition have focused predominantly on CD45 þ IL-6 responsive HMCL, and although this is a logical focus for preliminary investigation, it must be stressed that such target cell populations represents only a subset of MM cells. Furthermore, patients may demonstrate mixed populations of both CD45À and CD45 þ MM cells. 15 Importantly, we have demonstrated the effectiveness of CYT387 against NCI-H929, a HMCL considered to have an IL-6 non-responsive phenotype, suggesting that CYT387 will be effective against a range of MM phenotypes, whereas others 20 have reported only limited success against CD45À MM, using alternative JAK inhibitors. Our data demonstrating synergy between CYT387 and bortezomib, or melphalan against several HMCL and primary MM tumour cells confirms previously published work. 20 Available data suggests that the inhibition of JAK in MM cells may have downstream effects other than the direct inhibition of the JAK/STAT pathway. The importance of IL-6 in MM cell survival has been well characterised in terms of the JAK/STAT pathway, but there is now increasing evidence of IL-6-induced PI3K/AKT activation 19, 33 and Ras/MAPK activation 21, [33] [34] [35] [36] in various HMCL. Given the established importance of both the PI3K/AKT and Ras/MAPK pathways in addition to the JAK/STAT pathway in MM, small molecule inhibitors that could modulate all three could have enormous clinical potential. Investigating the effects of JAK inhibition on the PI3K/AKT and Ras/MAPK pathways has yielded contrasting results. AZD1480 and AG490 have been shown to reduce IL-6-induced activation of Ras/ MAPK, 21, 23 but AG490 in the hands of others showed no decrease in IL-6-induced Ras/MAPK activation. 34 The JAK inhibitor INCB20 could inhibit IL-6-induced Ras/MAPK activation in MM.1S cells, but did not affect constitutive Ras/MAPK activation in INA-6 cells. 19 The inhibition of JAK with AG490 could also abrogate AKT activation in phosphatase and tensin homolog-mutated OPM2 MM cells. 33 Similarly, INCB20 could also inhibit IL-6-induced p-AKT, but had no effect on IGF-1-induced p-AKT in INA-6 cells. 19 Variability in the available data may be the result of differences in inhibitors and heterogeneity amongst HMCL that are commonly studied. In our study, there was a significant reduction in IL-6 and IGF-1-induced p-ERK in U266 cells, as well as a dramatic reduction of IL-6 and IGF-1-induced p-AKT in OCI-MY1 cells, supporting the data of others that suggests JAK inhibition may have broader anti-MM activity than would be initially expected. The inhibition of IL-6-induced JAK/STAT and PI3K/AKT signalling may also result in a reduction in IL-6 receptor expression on the surface of MM cells, 33 which could also lead to a reduction in the pro-survival effects of IL-6.
The profound anti-proliferative effect of CYT387 on various HMCL after a single dose is an important demonstration of its effectiveness. Furthermore, the ability of CYT387 to inhibit HMCL growth even in the presence of exogenous IL-6, which has been shown many times as a mediator of drug resistance [11] [12] [13] is noteworthy. This significant effect of JAK inhibition may be the result of HMCL having some dependence on JAK/STAT for proliferative signals, or more likely, the involvement and subsequent inhibition of alterative signalling pathways mentioned above. The effect on proliferation is also seen in the cell cycling analysis, which demonstrates that CYT387 can prevent cell cycling. Also of interest was the additional polyploidy population (8n) induced by CYT387 treatment, which may suggest a role for JAK signalling leading to cell cycle regulation or may be the result of CYT387 inhibition of other kinases involved in cell cycle, such as aurora B, aurora C, cyclin A or cyclin B as described by Pardanani et al. 17 A direct or downstream effect of JAK inhibitors on cell cycling proteins is supported by studies on other JAK inhibitors, Scuto et al. 23 found AZD1480 inhibited cyclin D2 in two HMCL. The induction of apoptosis in MM cells in primary marrow CCs using clinically relevant low-micromolar doses is a critical demonstration of the potential of CYT387. In contrast, other studies inhibiting IL-6 signalling have failed to demonstrate any convincing evidence of apoptosis when MM cells were treated in the presence of BMSC. 35 The investigators suggested that this might represent MM cell independence from IL-6 in the presence of BMSC. Our findings with CYT387 could be interpreted as either refuting the latter or alternatively being consistent with the capacity of JAK signalling inhibition to interrupt non-IL6-mediated survival pathways. Consistent with the latter was that the primary MM samples treated with CYT387 were representative of autologous whole marrow CCs with the CD38 þ CD45À MM cells making up between 4 and 67% of treated cells. Therefore, the demonstration that CYT387 was able to induce apoptosis of these heavily treated MM cells was particularly encouraging. Our pre-clinical evaluation of CYT387 has demonstrated promising anti-myeloma effects of an orally bioavailable compound already through phase I clinical trials. We show the inhibition of important signalling pathways in MM cells, the subsequent reduction in cell viability, proliferation and corresponding inhibition of the cell cycle. Furthermore, we present specific evidence of the induction of apoptosis in both primary MM cells and HMCL. The synergy demonstrated by CYT387 with common myeloma therapies bortezomib and melphalan make it a very attractive compound for further study in the clinic.
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